Anticancer Therapies – Products

SomaLogic has announced it has signed a licensing agreement with OncoHost.

Natural killer (NK) cells are immune cells capable of killing target cells and can be genetically modified to express chimeric antigen receptors (CARs). CAR NK-cell therapy is an innovative type of cancer immunotherapy for solid tumors and hematological malignancies.

Discovery of novel immunotherapies that specifically target and enhance the T cell response against cancer is a rapidly expanding research area. Robust and relevant in vitro models for evaluation of these immunotherapies is essential throughout their development.

Currently, various treatments are available to cancer patients, such as chemotherapy, targeted therapy and immunotherapy. Targeted therapy is a type of precision medicine that targets the proteins that control the growth, division and spread of cancer cells.

Life science specialists, AMSBIO, have made a new strategic investment to enhance the level of support to its sizeable and growing base of customers across the European Union.

Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. However, not all patients respond to immunotherapy, and combination immunotherapies increase cost of treatment and heighten the risk for toxicity-related adverse events.

After years of research and experience by our technicians, we successfully established the "Star Staining" site-specific labeling platform and developed a series of exclusive fluorescent-labeled proteins with "Star Standard" quality.

One of the more promising types of cancer immunotherapy involves engineering immune cells to recognize and attack cancer.

AMSBIO report that researchers from the Medical University of Vienna (Austria), have used Lipidure® - CM5206 to coat channels in their novel microfluidic devices, to prevent cell adhesion.

The successful use of immunotherapies to help combat cancer has expanded rapidly in the last few years, with many therapies now approved for clinical use.